Butamben

Summary

Butamben (CHEMBL127516) is an approved small-molecule local anaesthetic.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 193.24 Da · C11H15NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL127516
Name	Butamben
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2482
ChEBI	CHEBI:3231
Molecular formula	C11H15NO2
Molecular weight	193.24
InChIKey	IUWVALYLNVXWKX-UHFFFAOYSA-N

SMILES: CCCCOC(=O)C1=CC=C(C=C1)N

IUPAC name: butyl 4-aminobenzoate

ChEBI definition: An amino acid ester resulting from the formal condensation of the carboxy group of 4-aminobenzoic acid with the hydroxy group of butan-1-ol. Its local anaesthetic properties have been used for surface anaesthesia of the skin and mucous membranes, and for relief of pain and itching associated with some anorectal disorders.

Pharmacological roles (ChEBI): local anaesthetic.

Also known as: ABBOTT-34842 FREE BASE, Butamben, Butesin, Butyl aminobenzoate, Butyl p-aminobenzoate, Butyl paba, NSC-128464, P-aminobenzoic acid butyl ester, SID11112245, SID11532999, SID17389507, SID104171291

Parent form; salt/anhydrous children: CHEMBL3142541

Patent coverage: 1,321 distinct patent families (4,333 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Nuclear receptor ROR-gamma, Prelamin-A/C, Ferritin light chain, Thyrotropin receptor, Beta-lactamase, 3’,5’-cyclic-AMP phosphodiesterase 4D, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 3A4, Cytochrome P450 2C19.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 19 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP1A2	6.5	AC50	316.2	nM	CHEMBL_ACT_6055722
Q63921	6.22	AC50	600	nM	CHEMBL_ACT_25174625
LMNA	5.15	Potency	7080	nM	CHEMBL_ACT_3647038
CYP2C19	5	Potency	10000	nM	CHEMBL_ACT_4016285
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_5010110
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_5078481
CYP3A4	5	AC50	10000	nM	CHEMBL_ACT_6040879
CYP2C19	5	AC50	10000	nM	CHEMBL_ACT_6044082

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).